[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-who-owns-vertex-pharmaceuticals-top-shareholders-and-recent-insider-trades-ES":222},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218],{"slug":151,"title":152,"modified":153},"bloomberg","Bloomberg","2025-01-16T14:23:44",{"slug":155,"title":156,"modified":157},"morningstar","Morningstar","2025-01-16T14:25:16",{"slug":159,"title":160,"modified":161},"sentieo","Sentieo","2025-01-16T17:58:27",{"slug":163,"title":164,"modified":165},"googlefinance","Google Finance","2025-01-17T19:39:37",{"slug":167,"title":168,"modified":169},"tradingview","TradingView","2025-01-16T18:17:01",{"slug":171,"title":172,"modified":173},"factset","Factset","2025-01-16T18:20:16",{"slug":175,"title":176,"modified":177},"finviz","Finviz","2025-01-16T18:23:40",{"slug":179,"title":180,"modified":181},"ycharts","YCharts","2025-01-16T18:32:19",{"slug":183,"title":184,"modified":185},"marketbeat","MarketBeat","2025-03-11T00:27:23",{"slug":187,"title":188,"modified":189},"benzinga","Benzinga","2025-03-11T00:31:00",{"slug":191,"title":192,"modified":193},"gurufocus","Gurufocus","2025-03-11T00:31:12",{"slug":195,"title":196,"modified":197},"fast-graphs","FAST Graphs","2025-03-11T00:31:19",{"slug":199,"title":200,"modified":201},"tipranks","TipRanks","2025-03-11T00:31:26",{"slug":203,"title":204,"modified":205},"seeking-alpha","Seeking Alpha","2025-03-11T00:31:45",{"slug":207,"title":208,"modified":209},"thestreet","TheStreet","2025-03-11T00:31:52",{"slug":211,"title":212,"modified":213},"investing-com","Investing.com","2025-03-11T00:32:00",{"slug":215,"title":216,"modified":217},"zacks","Zacks","2025-03-26T15:40:40",{"slug":219,"title":220,"modified":221},"alphasense","AlphaSense","2025-03-11T00:32:15",{"post":223,"seo":259,"relatedPosts":265,"suggestedPosts":341},{"id":224,"title":225,"date":226,"modified":227,"excerpt":228,"content":229,"wordCount":230,"lang":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":239,"editor":245,"categories":250,"relatedPosts":256,"seo":257},87720,"¿A quién pertenece Vertex Pharmaceuticals? Principales accionistas y últimas operaciones con información privilegiada","2026-01-03T13:05:00","2026-01-03T11:44:27","\u003Cp>A continuación se muestra quién tiene las mayores participaciones en Vertex Pharmaceuticals en la actualidad y qué sugieren las recientes tendencias de propiedad y de información privilegiada sobre la confianza en el poder de los beneficios a largo plazo de la empresa y la durabilidad de la cartera de proyectos.\u003C\u002Fp>\n","\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=36235&tid=2662297&ref=srk6m3\">\u003Cstrong>Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)\u003C\u002Fstrong>\u003C\u002Fa> es una empresa de biotecnología centrada en el desarrollo de tratamientos para enfermedades graves, con su negocio principal anclado en las terapias de la fibrosis quística. Las acciones cotizaban recientemente en torno a \u003Cstrong> 452 dólares por título\u003C\u002Fstrong>, lo que supone una capitalización bursátil de unos \u003Cstrong> 114.700 millones de dólares\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\n\n\u003Cp>Vertex Pharmaceuticals se ha forjado una reputación por sus elevados márgenes, su fuerte generación de efectivo y su balance de caja neto. Ver quién posee Vertex Pharmaceuticals y las últimas operaciones con información privilegiada ayuda a mostrar cómo los grandes inversores y los directivos de la empresa parecen estar posicionándose en torno a las acciones en la actualidad.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\" target=\"_blank\" rel=\"noreferrer noopener\">Descubra el potencial de revalorización de sus acciones favoritas utilizando el nuevo modelo de valoración de TIKR (es gratuito) >>>.\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-who-are-vertex-pharmaceuticals-top-shareholders\">\u003Cstrong>\u003Cstrong>¿Quiénes son los principales accionistas de Vertex Pharmaceuticals?\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"1466\" height=\"821\" data-public-id=\"images\u002FVRTX-2\u002FVRTX-2.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1466,h_821,c_scale\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA\" alt=\"Vertex Pharmaceuticals stock\" class=\"wp-post-87720 wp-image-87729\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1767440244\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA 1466w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_168,c_scale\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_573,c_scale\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_430,c_scale\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_672,c_scale\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_784,c_scale\u002Ff_webp,q_auto\u002Fv1767440244\u002Fimages\u002FVRTX-2\u002FVRTX-2.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1466px) 100vw, 1466px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Principales accionistas de Vertex Pharmaceuticals\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>La base accionarial de Vertex Pharmaceuticals está liderada por grandes inversores institucionales que tienden a mantenerse a lo largo de los ciclos de mercado, lo que puede ayudar a mantener relativamente estable la propiedad a largo plazo. Los últimos registros muestran que los gestores activos ajustan sus posiciones en ambas direcciones en lugar de señalar un cambio claro.\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>Capital World Investors\u003C\u002Fstrong>: 25.910.587 acciones (10,21%), \u003Cstrong> 11.720 millones de dólares\u003C\u002Fstrong>. Recorta 2.821.556 acciones (-9,82%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>The Vanguard Group\u003C\u002Fstrong>: 24.098.786 acciones (9,50%), \u003Cstrong> 10.90B$ de valor\u003C\u002Fstrong>. Añadió 240.666 acciones (+1,01%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Capital Research Global Investors\u003C\u002Fstrong>: 16.553.281 acciones (6,52%), \u003Cstrong> 7.480 millones de dólares\u003C\u002Fstrong>. Añadidas 444.990 acciones (+2,76%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>BlackRock Institutional Trust Company\u003C\u002Fstrong>: 14.470.200 acciones (5,70%), \u003Cstrong> 6.540 millones de dólares\u003C\u002Fstrong>. Añadidas 317.502 acciones (+2,24%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>State Street Investment Management (US)\u003C\u002Fstrong>: 11.606.000 acciones (4,57%), \u003Cstrong> 5.250 millones de dólares\u003C\u002Fstrong>. Recorta 169.227 acciones (-1,44%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Geode Capital Management\u003C\u002Fstrong>: 5.973.745 acciones (2,35%), \u003Cstrong> valor de 2.700 millones de dólares\u003C\u002Fstrong>. Añadió 44.998 acciones (+0,76%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Invesco Capital Management (Fondo QQQ)\u003C\u002Fstrong>: 5.374.674 acciones (2,12%), \u003Cstrong> valor de 2.430 millones de dólares\u003C\u002Fstrong>. Recorta 14.688 acciones (-0,27%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Wellington Management\u003C\u002Fstrong>: 4.772.042 acciones (1,88%), \u003Cstrong> 2.160 millones de dólares\u003C\u002Fstrong>. Recorta 41.344 acciones (-0,86%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Capital International Investors\u003C\u002Fstrong>: 4.689.059 acciones (1,85%), \u003Cstrong> valor de 2.120 millones de dólares\u003C\u002Fstrong>. Añadió 2.053.156 acciones (+77,89%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>AllianceBernstein L.P.\u003C\u002Fstrong>: 4.522.586 acciones (1,78%), \u003Cstrong> 2.040 millones de dólares\u003C\u002Fstrong>. Añadidas 144.266 acciones (+3,30%).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>JPMorgan Asset Management\u003C\u002Fstrong>: 4.387.658 acciones (1,73%), \u003Cstrong> por un valor de 1.980 millones de dólares\u003C\u002Fstrong>. Añadió 363.280 acciones (+9,03%).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>Para los inversores, esta mezcla de recorte y acumulación sugiere que Vertex Pharmaceuticals sigue siendo una participación institucional básica, aunque los grandes gestores parecen selectivos a los actuales niveles de valoración.\u003C\u002Fp>\n\n\n\n\u003Ch3 class=\"wp-block-heading\" id=\"h-hedge-fund-highlights\">Hechos destacados de los fondos de cobertura\u003C\u002Fh3>\n\n\n\n\u003Cp>Un movimiento notable el pasado trimestre fue el de \u003Cstrong>Two Sigma Advisers\u003C\u002Fstrong>, fundado por \u003Cstrong>John Overdeck\u003C\u002Fstrong>, que aumentó su posición en \u003Cstrong>Vertex Pharmaceuticals\u003C\u002Fstrong> en más de \u003Cstrong>un 1,100%\u003C\u002Fstrong>. Aunque el valor en dólares sigue siendo relativamente modesto, la magnitud del aumento sugiere que la empresa podría estar valorando más positivamente el perfil de riesgo-recompensa de Vertex Pharmaceuticals.\u003C\u002Fp>\n\n\n\n\u003Cp>Otro comprador activo fue \u003Cstrong>Tang Capital Management\u003C\u002Fstrong>, dirigida por su fundador \u003Cstrong>Kevin Tang\u003C\u002Fstrong>, que aumentó su participación en Vertex Pharmaceuticals en aproximadamente \u003Cstrong>un 700%\u003C\u002Fstrong>. La empresa posee ahora acciones por valor de más de \u003Cstrong> 31 millones de dólares\u003C\u002Fstrong>, lo que indica que Tang Capital podría estar posicionándose en torno al valor de la cartera a largo plazo.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>Capula Management\u003C\u002Fstrong>, fundada por \u003Cstrong>Yan Huo\u003C\u002Fstrong>, también aumentó considerablemente su exposición, incrementando su posición en casi \u003Cstrong>un 650%\u003C\u002Fstrong>. Aunque el tamaño de la posición sigue siendo pequeño, la magnitud del aumento sugiere que la empresa vio un punto de entrada atractivo.\u003C\u002Fp>\n\n\n\n\u003Cp>Por su parte, \u003Cstrong>Citadel Advisors\u003C\u002Fstrong>, fundada por \u003Cstrong>Ken Griffin\u003C\u002Fstrong>, aumentó sus participaciones en Vertex Pharmaceuticals en más de \u003Cstrong>un 500%\u003C\u002Fstrong>, creando una posición por valor de unos \u003Cstrong> 68 millones de dólares\u003C\u002Fstrong>, lo que puede reflejar una asignación táctica más que una apuesta de alta convicción.\u003C\u002Fp>\n\n\n\n\u003Cp>Para los inversores, la actividad de los hedge funds parece constructiva pero comedida, con una acumulación selectiva más que una compra generalizada.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Siga a los principales accionistas de más de 50.000 valores mundiales (es gratis) >>>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-vertex-pharmaceuticals-recent-insider-trades\">\u003Cstrong>\u003Cstrong>Últimas operaciones con información privilegiada de Vertex Pharmaceuticals\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"1480\" height=\"1034\" data-public-id=\"images\u002FVRTX-3\u002FVRTX-3.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1480,h_1034,c_scale\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA\" alt=\"Vertex Pharmaceuticals stock\" class=\"wp-post-87720 wp-image-87730\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1767440251\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA 1480w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_210,c_scale\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_715,c_scale\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_537,c_scale\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_838,c_scale\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_978,c_scale\u002Ff_webp,q_auto\u002Fv1767440251\u002Fimages\u002FVRTX-3\u002FVRTX-3.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1480px) 100vw, 1480px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Últimas operaciones con información privilegiada de Vertex Pharmaceuticals\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>Las operaciones con información privilegiada pueden ofrecer un contexto sobre cómo los ejecutivos y directores pueden estar gestionando la exposición personal a las acciones. Los archivos recientes de Vertex Pharmaceuticals muestran actividad de venta entre varias personas con información privilegiada, con compras limitadas.\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>Jeffrey M. Leiden (ejecutivo y director)\u003C\u002Fstrong>: Vendió más de 60.000 acciones a precios que oscilaron entre ~440 y ~455 dólares; registró 63.781 acciones a \u003Cstrong> 86,52 dólares\u003C\u002Fstrong>.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Charles F. Wagner Jr. (directivo)\u003C\u002Fstrong>: Vendió 14.000 acciones a precios entre ~$451 y ~$461.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Jonathan Prim Biller (directivo)\u003C\u002Fstrong>: Vendió 347 acciones a un precio aproximado de \u003Cstrong> 449 dólares\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>Para los inversores, la actividad de la información privilegiada parece cautelosa, con ventas repartidas entre los niveles de precios y registros que pueden estar relacionados con la compensación o la gestión de la cartera personal más que con una señal clara sobre las perspectivas futuras de Vertex Pharmaceuticals.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Ver datos recientes de operaciones con información privilegiada de más de 50.000 valores mundiales (Es gratis) >>>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-the-ownership-amp-insider-trade-data-tell-us\">Qué nos dicen los datos sobre propiedad y operaciones con información privilegiada\u003C\u002Fh2>\n\n\n\n\u003Cp>La propiedad de Vertex Pharmaceuticals sigue estando en manos de grandes inversores institucionales, lo que proporciona estabilidad. El posicionamiento de los fondos de cobertura muestra una acumulación selectiva junto con un recorte, mientras que la actividad de la información privilegiada se inclina hacia la venta, pero no parece agresiva en relación con la propiedad total.\u003C\u002Fp>\n\n\n\n\u003Cp>Para los inversores, los datos combinados sugieren que Vertex Pharmaceuticals sigue considerándose una empresa de alta calidad, aunque tanto los inversores internos como los gestores activos se muestran comedidos con los niveles de valoración actuales, en lugar de mostrar una fuerte tendencia.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-value-any-stock-in-under-60-seconds-it-s-free\">\u003Cstrong>\u003Cstrong>\u003Cstrong>Valore cualquier acción en menos de 60 segundos (es gratis)\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>Con la \u003Cstrong>nueva herramienta Valuation Model\u003C\u002Fstrong> de TIKR, puede estimar el precio potencial de una acción en menos de un minuto.\u003C\u002Fp>\n\n\n\n\u003Cp>Todo lo que necesita son tres simples datos:\u003C\u002Fp>\n\n\n\n\u003Col class=\"wp-block-list\">\n\u003Cli>\u003Cem>Crecimiento de los ingresos\u003C\u002Fem>\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cem>Márgenes operativos\u003C\u002Fem>\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cem>Múltiplo PER de salida\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Fol>\n\n\n\n\u003Cp>A partir de ahí, TIKR calcula el precio potencial de la acción y la rentabilidad total en los \u003Cstrong>escenarios\u003C\u002Fstrong> \u003Cstrong>alcista, bajista y básico\u003C\u002Fstrong>, para que pueda ver rápidamente si una acción parece \u003Cstrong>infravalorada o sobrevalorada\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\n\n\u003Cp>Si no está seguro de qué introducir, TIKR rellena automáticamente cada entrada utilizando las estimaciones de consenso de los analistas, ofreciéndole un punto de partida rápido y fiable.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\" target=\"_blank\" rel=\"noreferrer noopener\">Vea el valor real de una acción en menos de 60 segundos (gratis con TIKR) >>>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n",872,"es","\u002Fblog\u002Fwho-owns-vertex-pharmaceuticals-top-shareholders-and-recent-insider-trades","who-owns-vertex-pharmaceuticals-top-shareholders-and-recent-insider-trades","images\u002FVertex-Pharmaceuticals-stock_8773116e32\u002FVertex-Pharmaceuticals-stock_8773116e32","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767440573\u002Fimages\u002FVertex-Pharmaceuticals-stock_8773116e32\u002FVertex-Pharmaceuticals-stock_8773116e32.png?_i=AA",{"altText":237,"imageCredit":238},"Who Owns Vertex Pharmaceuticals? Top Shareholders and Recent Insider Trades","@ภาพของNatee Jindakum via Canva",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":244},"Nikko Henson","nikkotikr","author","",[],{"name":246,"slug":247,"role":248,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":249},"Thomas Richmond","thomastikr","editor",[],[251],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},"Reseñas de Acciones","reviews","\u002Fblog\u002Fcategory\u002Freviews",0,[],{"title":237,"metaDesc":258,"opengraphDescription":258,"twitterTitle":237,"twitterDescription":258},"Here’s who holds the biggest stakes in Vertex Pharmaceuticals today and what recent ownership and insider trends suggest about confidence in the company’s long-term earnings power and pipeline durability.",{"title":237,"description":258,"twitterTitle":237,"twitterDescription":258,"author":240,"articlePublisher":260,"articlePublishedTime":226,"articleModifiedTime":227,"twitterLabel1":261,"twitterData1":262,"ogTitle":237,"ogDescription":258,"ogUrl":232,"ogImage":235,"ogImageWidth":263,"ogImageHeight":264,"ogImageSecureUrl":235,"ogImageAlt":237,"twitterImage":235},"TIKR.com","Tiempo de lectura estimado","6 minutes",1200,630,[266,281,296,311,326],{"id":255,"title":267,"date":268,"excerpt":269,"wordCount":270,"uri":271,"slug":272,"cloudinaryAssetId":273,"featuredImageOriginalUrl":274,"featuredImageMetadata":275,"author":276,"categories":278,"relatedPosts":280},"¿A quién pertenece Regeneron Pharmaceuticals? Principales accionistas y últimas operaciones con información privilegiada","2026-01-03 12:35:00","A continuación se indica quiénes tienen las mayores participaciones en Regeneron Pharmaceuticals en la actualidad y qué sugieren las recientes tendencias de propiedad y de información privilegiada sobre la confianza en el poder de los beneficios a largo plazo de la empresa y la solidez de su cartera de proyectos.",994,"\u002Fblog\u002Fwho-owns-regeneron-pharmaceuticals-top-shareholders-and-recent-insider-trades","who-owns-regeneron-pharmaceuticals-top-shareholders-and-recent-insider-trades","images\u002FRegeneron-Pharmaceuticals-stock-1\u002FRegeneron-Pharmaceuticals-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767438954\u002Fimages\u002FRegeneron-Pharmaceuticals-stock-1\u002FRegeneron-Pharmaceuticals-stock-1.png?_i=AA",{"altText":267},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":277},[],[279],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":282,"date":283,"excerpt":284,"wordCount":285,"uri":286,"slug":287,"cloudinaryAssetId":288,"featuredImageOriginalUrl":289,"featuredImageMetadata":290,"author":291,"categories":293,"relatedPosts":295},"¿A quién pertenece Zimmer Biomet? Principales accionistas y últimas operaciones con información privilegiada","2026-01-03 12:05:00","A continuación se indica quiénes son los principales accionistas de Zimmer Biomet en la actualidad y qué sugieren las recientes tendencias de propiedad y de información privilegiada sobre la confianza en la demanda de procedimientos a largo plazo y las perspectivas de beneficios de la empresa.",816,"\u002Fblog\u002Fwho-owns-zimmer-biomet-holdings-top-shareholders-and-recent-insider-trades","who-owns-zimmer-biomet-holdings-top-shareholders-and-recent-insider-trades","images\u002FZimmer-Biomet-stock\u002FZimmer-Biomet-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767437498\u002Fimages\u002FZimmer-Biomet-stock\u002FZimmer-Biomet-stock.png?_i=AA",{"altText":282},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":292},[],[294],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":297,"date":298,"excerpt":299,"wordCount":300,"uri":301,"slug":302,"cloudinaryAssetId":303,"featuredImageOriginalUrl":304,"featuredImageMetadata":305,"author":306,"categories":308,"relatedPosts":310},"¿A quién pertenece Jazz Pharmaceuticals? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 22:23:40","A continuación, se muestra quiénes son los principales accionistas de Jazz Pharmaceuticals en la actualidad y qué sugieren los recientes cambios en la propiedad y la actividad de información privilegiada sobre la confianza en las perspectivas de beneficios a largo plazo de la empresa.",868,"\u002Fblog\u002Fwho-owns-jazz-pharmaceuticals-top-shareholders-and-recent-insider-trades","who-owns-jazz-pharmaceuticals-top-shareholders-and-recent-insider-trades","images\u002FJazz-Pharmaceuticals-stock-1\u002FJazz-Pharmaceuticals-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767392737\u002Fimages\u002FJazz-Pharmaceuticals-stock-1\u002FJazz-Pharmaceuticals-stock-1.png?_i=AA",{"altText":297},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":307},[],[309],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":312,"date":313,"excerpt":314,"wordCount":315,"uri":316,"slug":317,"cloudinaryAssetId":318,"featuredImageOriginalUrl":319,"featuredImageMetadata":320,"author":321,"categories":323,"relatedPosts":325},"¿A quién pertenece IQVIA Holdings? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 21:45:26","A continuación, se explica quién posee las mayores participaciones en IQVIA Holdings en la actualidad y qué sugieren los recientes cambios en la propiedad sobre la confianza en las perspectivas de crecimiento a largo plazo de la compañía.",925,"\u002Fblog\u002Fwho-owns-iqvia-holdings-top-shareholders-and-recent-insider-trades","who-owns-iqvia-holdings-top-shareholders-and-recent-insider-trades","images\u002FIQVIA-Holdings-stock\u002FIQVIA-Holdings-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767390039\u002Fimages\u002FIQVIA-Holdings-stock\u002FIQVIA-Holdings-stock.png?_i=AA",{"altText":312},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":322},[],[324],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":327,"date":328,"excerpt":329,"wordCount":330,"uri":331,"slug":332,"cloudinaryAssetId":333,"featuredImageOriginalUrl":334,"featuredImageMetadata":335,"author":336,"categories":338,"relatedPosts":340},"¿A quién pertenece Incyte Corporation? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 19:38:12","A continuación se muestra quién tiene las mayores participaciones en Incyte Corporation en la actualidad y qué sugieren los recientes cambios en la propiedad y la actividad de información privilegiada sobre la confianza en las perspectivas de beneficios y proyectos a largo plazo de la empresa.",893,"\u002Fblog\u002Fwho-owns-incyte-corporation-top-shareholders-and-recent-insider-trades","who-owns-incyte-corporation-top-shareholders-and-recent-insider-trades","images\u002FIncyte-stock\u002FIncyte-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767382563\u002Fimages\u002FIncyte-stock\u002FIncyte-stock.png?_i=AA",{"altText":327},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":337},[],[339],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],[342,361,376,391,406,421,441,456,471,488],{"id":255,"title":343,"date":344,"excerpt":345,"wordCount":346,"uri":347,"slug":348,"cloudinaryAssetId":-1,"featuredImageOriginalUrl":349,"featuredImageMetadata":350,"author":351,"categories":355,"relatedPosts":360},"Por qué las acciones de Broadcom (AVGO) subieron un 50% en 2025","2026-01-02 14:45:00","Broadcom (AVGO), que ha caído un 15% desde sus máximos históricos, es un valor tecnológico de gran capitalización que ha devuelto un 50% a sus accionistas en 2025. ",656,"\u002Fblog\u002Fwhy-broadcom-nasdaq-avgo-stock-rose-50-in-2025","why-broadcom-nasdaq-avgo-stock-rose-50-in-2025","https:\u002F\u002Ftikr1.wpengine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F01\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-8-600x400.png",{"altText":343},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":354},"Aditya Raghunath","adityatikr",[],[356],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},"Inversión General","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",[],{"id":255,"title":362,"date":363,"excerpt":364,"wordCount":365,"uri":366,"slug":367,"cloudinaryAssetId":368,"featuredImageOriginalUrl":369,"featuredImageMetadata":370,"author":371,"categories":373,"relatedPosts":375},"Por qué las acciones de Kratos Defense subieron un 190% en 2025","2026-01-02 14:15:00","Las acciones de Kratos Defense casi triplicaron el patrimonio de los inversores el año pasado, ya que la empresa de seguridad sigue ampliando su foso competitivo. ",1160,"\u002Fblog\u002Fwhy-kratos-defense-nasdaq-ktos-stock-surged-190-in-2025","why-kratos-defense-nasdaq-ktos-stock-surged-190-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767361825\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7.png?_i=AA",{"altText":362},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":372},[],[374],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":377,"date":378,"excerpt":379,"wordCount":380,"uri":381,"slug":382,"cloudinaryAssetId":383,"featuredImageOriginalUrl":384,"featuredImageMetadata":385,"author":386,"categories":388,"relatedPosts":390},"Por qué las acciones de Dollar Tree subieron un 64% en 2025","2026-01-02 13:45:00","Las acciones de Dollar Tree subieron un 64% en 2025, aplastando los rendimientos del mercado en general, ya que el minorista de descuento se centró en sus esfuerzos de reconversión. ",966,"\u002Fblog\u002Fwhy-dollar-tree-nasdaq-dltr-stock-rose-64-in-2025","why-dollar-tree-nasdaq-dltr-stock-rose-64-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767360245\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956.png?_i=AA",{"altText":377},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":387},[],[389],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":392,"date":393,"excerpt":394,"wordCount":395,"uri":396,"slug":397,"cloudinaryAssetId":398,"featuredImageOriginalUrl":399,"featuredImageMetadata":400,"author":401,"categories":403,"relatedPosts":405},"Por qué las acciones de Nebius subieron un 200% en 2025","2026-01-02 12:00:00","Las acciones de Nebius, que han caído un 40% desde sus máximos históricos, se han triplicado con creces en 2025 a medida que ganan terreno en el mercado de la IA, en rápida expansión. ",888,"\u002Fblog\u002Fwhy-nebius-nasdaq-nbis-stock-rose-200-in-2025","why-nebius-nasdaq-nbis-stock-rose-200-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767353835\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87.png?_i=AA",{"altText":392},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":402},[],[404],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":407,"date":408,"excerpt":409,"wordCount":410,"uri":411,"slug":412,"cloudinaryAssetId":413,"featuredImageOriginalUrl":414,"featuredImageMetadata":415,"author":416,"categories":418,"relatedPosts":420},"Por qué las acciones de Asana cayeron un 32% en 2025","2026-01-02 11:15:00","Con una caída de más del 90% desde sus máximos históricos, las acciones de Asana siguieron registrando un rendimiento inferior al de los mercados más amplios en 2025. ",731,"\u002Fblog\u002Fwhy-asana-stock-fell-32-in-2025","why-asana-stock-fell-32-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767351571\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98.png?_i=AA",{"altText":407},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":417},[],[419],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":422,"date":423,"excerpt":424,"wordCount":425,"uri":426,"slug":427,"cloudinaryAssetId":428,"featuredImageOriginalUrl":429,"featuredImageMetadata":430,"author":431,"categories":435,"relatedPosts":440},"CaixaBank acaba de alcanzar máximos históricos. Podrá seguir subiendo en 2026?","2025-12-31 15:15:00","A pesar de un repunte masivo, nuestro modelo muestra que las acciones de CABK podrían rendir alrededor de un 15% hasta 2030 a medida que su negocio de seguros se dispare.",987,"\u002Fblog\u002Fcaixabank-just-hit-all-time-highs-can-the-stock-keep-climbing-in-2026","caixabank-just-hit-all-time-highs-can-the-stock-keep-climbing-in-2026","images\u002F2_873969caee\u002F2_873969caee","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767053079\u002Fimages\u002F2_873969caee\u002F2_873969caee.png?_i=AA",{"altText":422},{"name":432,"slug":433,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":434},"Wiltone Asuncion","wiltonetikr",[],[436],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},"Valoración","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":255,"title":442,"date":443,"excerpt":444,"wordCount":445,"uri":446,"slug":447,"cloudinaryAssetId":448,"featuredImageOriginalUrl":449,"featuredImageMetadata":450,"author":451,"categories":453,"relatedPosts":455},"Las acciones del Banco Bilbao Vizcaya Argentaria (BBVA) han subido un 110% este año, ¿todavía tienen recorrido?","2025-12-31 14:30:00","A pesar de unos márgenes operativos de primera clase, nuestro modelo prevé una rentabilidad anualizada del -1,2% para las acciones de BBVA en los próximos dos años.",1095,"\u002Fblog\u002Fup-110-this-year-does-banco-bilbao-vizcaya-argentaria-bbva-stock-still-have-room-to-run","up-110-this-year-does-banco-bilbao-vizcaya-argentaria-bbva-stock-still-have-room-to-run","images\u002FCopy-of-Random-Featured-Image-1-1\u002FCopy-of-Random-Featured-Image-1-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1766137070\u002Fimages\u002FCopy-of-Random-Featured-Image-1-1\u002FCopy-of-Random-Featured-Image-1-1.png?_i=AA",{"altText":442},{"name":432,"slug":433,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":452},[],[454],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[],{"id":255,"title":457,"date":458,"excerpt":459,"wordCount":460,"uri":461,"slug":462,"cloudinaryAssetId":463,"featuredImageOriginalUrl":464,"featuredImageMetadata":465,"author":466,"categories":468,"relatedPosts":470},"Las acciones del Banco de Sabadell han subido un 300% en los últimos 3 años, ¿podrán continuar su racha en 2026?","2025-12-30 16:15:00","Esta es la razón por la que las acciones de Banco Sabadell han subido un 87% desde sus mínimos de 52 semanas. Las acciones de Banco Sabadell podrían alcanzar su precio objetivo de 3,58 euros en 2029. ",1088,"\u002Fblog\u002Fup-300-over-the-past-3-years-can-banco-de-sabadell-stock-continue-its-run-in-2026","up-300-over-the-past-3-years-can-banco-de-sabadell-stock-continue-its-run-in-2026","images\u002FCopy-of-Random-Featured-Image-2\u002FCopy-of-Random-Featured-Image-2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1766141023\u002Fimages\u002FCopy-of-Random-Featured-Image-2\u002FCopy-of-Random-Featured-Image-2.png?_i=AA",{"altText":457},{"name":432,"slug":433,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":467},[],[469],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[],{"id":255,"title":472,"date":473,"excerpt":474,"wordCount":475,"uri":476,"slug":477,"cloudinaryAssetId":478,"featuredImageOriginalUrl":479,"featuredImageMetadata":480,"author":481,"categories":485,"relatedPosts":487},"Por qué Netflix podría superar los 131 dólares por acción y alcanzar máximos históricos en 2026","2025-12-30 15:45:00","Netflix podría ofrecer una rentabilidad superior al 30% en 2027, ya que el crecimiento sostenido de los ingresos, la expansión de los márgenes y unas hipótesis de valoración estables respaldan una subida impulsada por los beneficios.",1212,"\u002Fblog\u002Fheres-why-netflix-could-pass-131-share-and-potentially-reach-all-time-highs-in-2026","heres-why-netflix-could-pass-131-share-and-potentially-reach-all-time-highs-in-2026","images\u002FFEATURED-IMAGE-MAKER-3_86684d6804\u002FFEATURED-IMAGE-MAKER-3_86684d6804","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1765994506\u002Fimages\u002FFEATURED-IMAGE-MAKER-3_86684d6804\u002FFEATURED-IMAGE-MAKER-3_86684d6804.png?_i=AA",{"altText":472},{"name":482,"slug":483,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":484},"Gian Estrada","giantikr",[],[486],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[],{"id":255,"title":489,"date":490,"excerpt":491,"wordCount":492,"uri":493,"slug":494,"cloudinaryAssetId":495,"featuredImageOriginalUrl":496,"featuredImageMetadata":497,"author":498,"categories":500,"relatedPosts":502},"Por qué este valor de mediana capitalización podría subir un 100% en los próximos dos años","2025-12-30 12:30:00","dLocal es un valor de crecimiento de mediana capitalización que cotiza con una valoración atractiva dadas sus estimaciones estelares de ingresos y beneficios. ",1121,"\u002Fblog\u002Fwhy-this-mid-cap-nasdaq-dlo-stock-could-surge-100-over-the-next-two-years","why-this-mid-cap-nasdaq-dlo-stock-could-surge-100-over-the-next-two-years","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767093096\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1.png?_i=AA",{"altText":489},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":499},[],[501],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[]]